These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9989621)

  • 1. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates.
    Plomp JJ; Molenaar PC; O'Hanlon GM; Jacobs BC; Veitch J; Daha MR; van Doorn PA; van der Meché FG; Vincent A; Morgan BP; Willison HJ
    Ann Neurol; 1999 Feb; 45(2):189-99. PubMed ID: 9989621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.
    Jacobs BC; O'Hanlon GM; Bullens RW; Veitch J; Plomp JJ; Willison HJ
    Brain; 2003 Oct; 126(Pt 10):2220-34. PubMed ID: 12876146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concanavalin A inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse.
    Bullens RW; Halstead SK; O'Hanlon GM; Veitch J; Molenaar PC; Willison HJ; Plomp JJ
    Muscle Nerve; 2005 Jun; 31(6):751-60. PubMed ID: 15793847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome.
    Jacobs BC; Bullens RW; O'Hanlon GM; Ang CW; Willison HJ; Plomp JJ
    Muscle Nerve; 2002 Apr; 25(4):549-58. PubMed ID: 11932973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates.
    Bullens RW; O'Hanlon GM; Goodyear CS; Molenaar PC; Conner J; Willison HJ; Plomp JJ
    Muscle Nerve; 2000 Jul; 23(7):1035-43. PubMed ID: 10882997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
    Halstead SK; Zitman FM; Humphreys PD; Greenshields K; Verschuuren JJ; Jacobs BC; Rother RP; Plomp JJ; Willison HJ
    Brain; 2008 May; 131(Pt 5):1197-208. PubMed ID: 18184663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome.
    Buchwald B; Bufler J; Carpo M; Heidenreich F; Pitz R; Dudel J; Nobile-Orazio E; Toyka KV
    Neurology; 2001 Jan; 56(1):67-74. PubMed ID: 11148238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes.
    Kanzaki M; Kaida K; Ueda M; Morita D; Hirakawa M; Motoyoshi K; Kamakura K; Kusunoki S
    J Neurol Neurosurg Psychiatry; 2008 Oct; 79(10):1148-52. PubMed ID: 18339728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal.
    O'Hanlon GM; Plomp JJ; Chakrabarti M; Morrison I; Wagner ER; Goodyear CS; Yin X; Trapp BD; Conner J; Molenaar PC; Stewart S; Rowan EG; Willison HJ
    Brain; 2001 May; 124(Pt 5):893-906. PubMed ID: 11335692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation of clinical symptoms and anti-ganglioside antibodies to MEPPs frequency increase in 8 cases of variant type Guillain-Barré syndrome.
    Kishi M; Fujioka T; Miura H; Sekine A; Iguchi H; Nakazora H; Kiyozuka T; Igarashi O; Ichikawa Y; Sugimoto H; Kurihara T; Irie S; Saito T
    J Peripher Nerv Syst; 2003 Jun; 8(2):82-90. PubMed ID: 12795712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.
    Schwerer B; Neisser A; Bernheimer H
    Infect Immun; 1999 May; 67(5):2414-20. PubMed ID: 10225903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-ganglioside complex antibodies in Miller Fisher syndrome.
    Kaida K; Kanzaki M; Morita D; Kamakura K; Motoyoshi K; Hirakawa M; Kusunoki S
    J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1043-6. PubMed ID: 16614007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury.
    O'Hanlon GM; Humphreys PD; Goldman RS; Halstead SK; Bullens RW; Plomp JJ; Ushkaryov Y; Willison HJ
    Brain; 2003 Nov; 126(Pt 11):2497-509. PubMed ID: 12937083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release.
    Roberts M; Willison H; Vincent A; Newsom-Davis J
    Lancet; 1994 Feb; 343(8895):454-5. PubMed ID: 7905957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guillain-Barré and Fisher syndromes: update on the pathophysiological role of antiganglioside antibodies].
    Kaida K
    Rinsho Shinkeigaku; 2012; 52(11):914-6. PubMed ID: 23196466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological spectrum of the Miller Fisher syndrome.
    Lo YL
    Muscle Nerve; 2007 Nov; 36(5):615-27. PubMed ID: 17657801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.
    Liu JX; Willison HJ; Pedrosa-Domellöf F
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3226-32. PubMed ID: 19255160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle.
    Kuwabara S; Misawa S; Takahashi H; Sawai S; Kanai K; Nakata M; Mori M; Hattori T; Yuki N
    J Neuroimmunol; 2007 Sep; 189(1-2):158-62. PubMed ID: 17673301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in Miller Fisher syndrome and related disorders.
    Overell JR; Willison HJ
    Curr Opin Neurol; 2005 Oct; 18(5):562-6. PubMed ID: 16155441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction.
    Buchwald B; Ahangari R; Toyka KV
    Neurosci Lett; 2002 Dec; 334(1):25-8. PubMed ID: 12431767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.